E-Learning

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug

Read more

MicroStrategy’s Nasdaq Entry Kicks Off New Era of Momentum Risk

(Bloomberg) -- MicroStrategy Inc.’s entry into the Nasdaq 100 opens up the largest corporate holder of Bitcoin to a new — and untapped – investor: the index-tracking juggernauts. Most Read from BloombergHow California Sees the World, and ItselfHong Kong's Expat Party Hub Reshaped by Chinese InfluxLondon’s Tube Fares Are Set to Rise by 4.6% Next YearYet Wall Street pros warn the oncoming march of these price-insensitive investors threatens a new source of vulnerability in a stock that has soared

Read more

Nucor's Q4 Guidance Misses The Mark, Hit By Steel Slowdown; Stock Slides

Nucor Corporation (NYSE:NUE) shares are trading lower premarket today. On Monday, the company provided fourth-quarter guidance, expecting EPS of $0.55 – $0.65 vs. the consensus of $0.86. The primary factor driving the expected earnings decline is lower earnings in the steel mills segment due to decreased volumes and lower average selling prices. The company projects earnings in the steel products segment to decline, reflecting the same trends. However, the raw materials segment is anticipated to

Read more